Walgreens Mulls Bond Sale As JPMorgan Gauges Investor Appetite: Report

Author: Nabaparna Bhattacharya | July 25, 2024 02:41pm

JP Morgan Chase & Co. (NYSE:JPM) is reportedly gauging investor interest in a possible issuance of high-yield bonds by Walgreens Boots Alliance, Inc. (NASDAQ:WBA), aimed at managing the drug-store chain’s recently downgraded near-term debt obligations.

Preliminary discussions on pricing suggest a yield in the vicinity of 7.5%, reported Bloomberg, citing people familiar with the discussions.

The specific size and duration of the deal have not been finalized. Walgreens currently holds a $1.16 billion note maturing on November 18, trading close to par, and a £300 million ($387 million) bond due in late 2025, as per Bloomberg data.

Should Walgreens proceed with a bond sale, it would mark their first issuance since being downgraded to junk status by both Moody’s Ratings and S&P Global Ratings.

Also Read:  Rite Aid Forges Path To Financial Recovery With Major Settlement: Report

This move would entail significantly higher costs, with the highest coupon rate currently at 4.8% on a 2044 bond issued a decade ago.

In January, Walgreens nearly halved its dividend following a CEO change. Meanwhile,  Rite Aid Corp (OTC:RADCQ) is in bankruptcy, CVS Health Corporation (NYSE:CVS) faces retail challenges, and Walmart Inc. (NYSE:WMT)

scrapped plans for low-cost clinics due to cost and reimbursement issues.

S&P’s recent BB downgrade indicates Walgreens’ leverage ratio could remain above five times into fiscal 2025 and beyond, Bloomberg added.

Price Action: WBA shares are trading higher by 2.24% to $11.41 at last check Thursday.

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo: refrina/Shutterstock.com

Read Next:

• Privacy Risks Flagged: Major Pharmacy Chains Share Customer Data With Authorities Without Warrant.

Posted In: CVS JPM RADCQ WBA WMT